Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.63 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 6/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 7/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 3/20 | 0.44 |
| ▸ | KIF5B | P33176 | 3/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427630 | 1.00 | ENPP1 (0.63) | ENPP1PDE10AEGFRACHEBACE1 | |
| Hydrochloric Acid SCHEMBL9097 | 0.99 | ENPP1 (0.62) | ENPP1PDE10AEGFRACHEBACE1 | |
| SCHEMBL1999978 | 0.94 | ENPP1 (0.54) | ENPP1PDE10AEGFRACHEBACE1 | |
| SCHEMBL3766549 | 0.91 | ENPP1 (0.52) | ENPP1PDE10AEGFRACHEBACE1 | |
| SCHEMBL364049 | 0.86 | ENPP1 (0.81) | ENPP1EGFRKDRFLT1RET | |
| SCHEMBL29359187 | 0.86 | ENPP1 (0.81) | ENPP1EGFRKDRFLT1RET | |
| SCHEMBL3239272 | 0.86 | ENPP1 (0.68) | ENPP1EGFRPDGFRB | |
| SCHEMBL17967514 | 0.85 | ENPP1 (0.59) | ENPP1PDE10AEGFRACHEBACE1 | |
| Hydrochloric Acid SCHEMBL3526531 | 0.85 | ENPP1 (0.79) | ENPP1EGFRPDGFRBKDRFLT1 | |
| SCHEMBL217338 | 0.84 | PDE10A (0.52) | ENPP1PDE10AEGFRACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 440 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| US-20170114027-A1 | NOVEL QUINAZOLINE DERIVATIVE LU1501 AND PREPARING METHOD AND APPLICATION THEREOF | Nanjing General Hospital of Nanjing Military Region of PLA (CN) | 2017-04-27 | — | — | US | claimed |
| US-9624179-B1 | Quinazoline derivative Lu1501 and preparing method and application thereof | Nanjing General Hospital of Nanjing Military Region of PLA (CN) | 2017-04-18 | — | — | US | claimed |
| EP-2155656-A2 | PROCESS FOR THE PREPARATION OF GEFITINIB | Cipla Limited (IN) | 2010-02-24 | — | — | EP | claimed |
| WO-2008125867-A2 | PROCESS FOR THE PREPARATION OF GEFITINIB | CIPLA LIMITED (IN) | 2008-10-23 | — | — | WO | claimed |
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC (KR) | 2026-05-21 | — | — | US | disclosed |
| EP-3941459-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| CN-113924092-B | Quinoline and quinazoline compounds and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-4506343-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | Voronoi Inc. (KR) | 2025-02-12 | — | — | EP | disclosed |
| CN-119192146-A | Inhibitor compound, application and medicine for treating cancer | 蚌埠医科大学 | 2024-12-27 | — | — | CN | disclosed |
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| US-5770603-A | ANTICARCINOGENIC AGENTS | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
| EP-0823900-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-02-18 | — | — | EP | disclosed |
| WO-1997038994-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-10-23 | — | — | WO | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996033980-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114027-A1 | NOVEL QUINAZOLINE DERIVATIVE LU1501 AND PREPARING METHOD AND APPLICATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, SKP1 | ENPP1 4315/4885PDE10A 1728/4885EGFR 3014/4885 |
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | PDGFRA, KIT, PDGFRB | ENPP1 2914/4885PDE10A 2763/4885EGFR 79/4885 |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | EGFR, ABL1, ERBB2 | ENPP1 2077/4885PDE10A 3998/4885EGFR 1/4885 |
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ERBB2, EGFR, ERBB4 | ENPP1 2568/4885PDE10A 3028/4885EGFR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.